WO2007138225A1 - Composition for controlling snoring, in the form of a nasal spray - Google Patents
Composition for controlling snoring, in the form of a nasal spray Download PDFInfo
- Publication number
- WO2007138225A1 WO2007138225A1 PCT/FR2007/051342 FR2007051342W WO2007138225A1 WO 2007138225 A1 WO2007138225 A1 WO 2007138225A1 FR 2007051342 W FR2007051342 W FR 2007051342W WO 2007138225 A1 WO2007138225 A1 WO 2007138225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- substance
- use according
- nasal
- substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/08—Mineral waters; Sea water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Definitions
- the present invention relates to the field of treatment and prevention of snoring and more particularly snoring in some big snorers.
- snoring vary from person to person. At the anatomical level, snoring occurs mainly when the airway in the throat (pharynx) narrows after relaxation of the muscles that normally keep the passage open. This narrowing causes turbulent airflow and vibrations at the soft palate and at the base of the tongue, creating the sound of snoring. In the big snorers is superimposed on a snoring whose origin is the pharynx nasal snoring.
- nasal snoring The two main causes of nasal snoring are nasal airway obstruction and deformity of the nose.
- an obstruction of the nasal passages congested or blocked nose
- the subject requires additional effort to inspire. This action can create a vacuum effect in the throat and a change in the airflow passages in the nasal cavity that cause snoring.
- obstruction of the nasal passages requires the subject to breathe through the mouth and is often associated with snoring from the throat.
- the onset of snoring in large snorers is due to several factors that interact simultaneously with each other: mainly pharyngeal vibrations and narrowing of the nasal passages.
- the vibrations in the pharynx are the consequence of a too long veil, a supine sleeping position and a narrowing of the oral cavity.
- the existence of a too long veil is the most easily understood factor. This hypertrophy of the veil affects the muscles of the latter relatively especially affects the fatty tissues that surround them, and the mucous membrane.
- the uvula elongates, the posterior pillars of the tonsils thicken and widen into two half curtains extending the veil downwards.
- the second factor responsible for the onset of snoring is the supine position (the position on the back of the sleeping body). This position causes the relaxed veil to rest on the posterior wall of the pharynx. In this anatomical position, the passage of the nasal inspiratory air can easily lift it, make it float and vibrate.
- the veil falls forward, and does not risk touching the posterior or even lateral wall of the pharynx; thus cleared it leaves wide open behind him the air corridor which is posterior to him and the air passes easily. But it is lying on the back that the veil is best applied on the pharynx. This is the usual position of the severe snorer, and it is in this position that the asphyxic risks are greatest.
- the narrowing of the oral cavity is the third element responsible for snoring. This narrowing is caused by obesity, nasal obstruction and retrognathism.
- snoring is the vibration of the soft palate and pharyngeal walls under the action of abnormally turbulent airflow. It is related to the anatomical and mechanical features of the pharynx and mucus which constitutes a superficial viscous layer of the pharyngeal tissues. Mucus is a physiological and anatomical element of importance because it constitutes the medium that will interact with the spray (the assets are projected and must act at this level). It is therefore particularly important to know precisely the physical and physiological characteristics of this biological environment.
- the inspiratory air will cross a deformable space, elastic and more or less narrowed. In this narrowing will appear changes of flow and pressure called Venturi phenomena, governed by the Bernouilli theorems, at the origin of the vibration of the walls.
- Venturi phenomena governed by the Bernouilli theorems, at the origin of the vibration of the walls.
- the walls of the orohypopharynx are soft, elastic and narrowed. Everything is thus brought together so that Venturi phenomenon occurs several times a second, which accounts for the vibration of the soft palate linked to the clatter of the latter against the walls of the pharynx.
- the soft veil touches the posterior wall of the pharynx, that it is repelled by a current of air coming from the nose, then that any force bring him back to the palace.
- this force is the voluntary contraction.
- passive nocturnal snoring when lying down this force is that of gravity, and when it is applied to a long and voluminous veil, this one tends spontaneously to stick on the pharynx.
- Nasal snoring is the result of narrowing of the nasal passages. The more the tissues relax or the more difficult the passage of air, the greater the risk of snoring.
- the sound breathing can be caused or accentuated by polyps in the nasal passages (a polyp is an elongated outgrowth that occurs on a mucous membrane); congestion of the nasal passages (colds, allergy, alcohol or tranquillizers absorption) and loosening of the tissues with age.
- the nasal cavity is lined with a pseudostratified epithelium that rests on a basement membrane, separating it from the deep submucosal layers.
- the submucosal layers are composed of mucus, seromucus and serous glands.
- Local blood flow is distributed to the cells through a network of small arteries, arterioles and arteriovenous anastomoses.
- Vascular capacitance formed by veins and cavernous sinusoids, determines the degree of opening of the nasal passages. The contraction or relaxation of this set of vessels is under the influence of the sympathetic system.
- the cavernous sinusoids are denser than the inferior and middle horns, and are composed of smooth muscle cells controlled by the sympathetic nervous system. A loss of sympathetic tone, or to a lesser degree a cholinergic stimulation causes engorgement of this erectile sinusoidal tissue.
- the opening of the nasal passages is controlled mainly by the changes that occur in the capacitance of the vessels. Resistance of the upper nasal passages and indeed responsible for two-thirds of the total air resistance of the airways. The predominant sites of nasal obstruction to the passage of air are the nasal vestibule, nasal valves and nasal turbinates.
- nasal cycle There are physiological variations in nasal opening, known as the "nasal cycle". These variations mainly result in changes in the capacitance of the blood vessels in the lower and middle horns. These changes alternate from one nasal cavity to another approximately every two to four hours in 70% of people. The posture is also involved in regulating the degree of vascular congestion. Nasal obstruction increases bilaterally when the subject is in the supine position, and increases unilaterally depending on the lateral position of the subject.
- the nasal origin of snoring is an increase in resistance to the passage of air from the upper nasal passages, and more precisely to the level of the nasal valve and the inferior and middle horns. This is the result of a physiopathological mechanism of congestion, resulting in dilation of the blood vessels, increased secretion of mucus, dilation of smooth muscle structures.
- the resistance to the passage of air increases and modifies the air flows causing soft tissue vibrations of the palate and the uvula.
- Snoring at a "standard” buzzer has a frequency between 200 and 2000 Hz, with decibel levels of up to 70 dB.
- the frequency varies according to the origin of snoring [Perez-Padilla JR, Slawinski E, LM Difrancesco, Feige RR, Remmers JE, Whitelaw WA. Characteristics of the snoring noise in patients with and without occlusive sleep apnea. Am Rev Respir Dis. 1993 Mar; 147 (3): 635-44].
- the snoring of big snorers can be quite powerful in intensity. The average of the subjects has a snoring between 40 and 50 dB, with subjects up to 80-90 dB and sometimes even 105 dB. It seems that nasal snoring has a lower intensity than oral snoring. In some big snorers, the intensity of snoring is such that it causes hearing problems in their partners.
- the set of changes and physiological disturbances that occur in the big snorers leads to a modification of the air flows at the mouth and nasal levels producing a very large snore, very characteristic both in terms of frequency, intensity and the profile of the recording spectrum.
- the big snorers simultaneously present changes in the airflow at the nose as well as vibration of the soft palate. There do not seem to be any changes - anatomical abnormalities typical of big snorers.
- the intensity and frequency of snoring are discriminating features, as we saw earlier in the Perez study. Indeed, Snoring of nasal and oral origin have different intensities and different frequencies. In large snorers, the different intensities are superimposed for the same frequency and the intensities are added at different frequencies, which gives this aspect of diffuse noise on the recording spectra.
- the vibration of the soft palate is mainly under the influence of air flows from the nasal passages (often increased following respiratory discomfort). This vibration is itself sustained by a decrease in the tone of the muscles of the pharynx and uvula and produces a local inflammation which in turn increases the atony.
- a first "vicious circle” is constituted and thus maintains the phenomenon of snoring.
- the vibration of the soft palate causes disturbances of the passage of air during inspiration and expiration and consequently an increase in respiratory effort in the nasal passages. This maintains localized inflammation, congestion and thus enhances the phenomenon.
- There is thus a second "vicious circle” which reinforces the phenomena causing snoring in the big snorers. This superposition or imbrication of several imbalances produces snoring of very high intensity and characteristic frequency in the big snorers [see figure in appendix].
- the products marketed against snoring are oil-based preparations for lubricating the mucous membranes of the pharynx or nasal passages. These products are often perceived as inefficient by a large majority of consumers. Indeed, it is often mentioned that these products act quickly but lose their effectiveness in the first hour of sleep, shortly after application.
- the essential oils used in these preparations are, for some of them, not devoid of toxicity. Certain essential oils are indeed subject to restrictions of use and warnings following the demonstration of their toxicity reported by the pharmacovigilance surveys.
- the spraying of oily preparations in the pharynx and nasal is associated with the risk of oily pneumonitis, due to the passage of lipid droplets in the lungs.
- the French Health authorities AFSSAPS
- the risk of passage to the pulmonary level of the oils contained in these preparations represents a certain risk for the safety of the consumer.
- composition which is preferably in the form of a nasal spray, said composition comprising:
- a first substance or combination of substances providing a decongestant action to increase the nasal light by a sympathetic action on the smooth muscle, a vasoconstrictor action of the blood vessels and a local anti-inflammatory action to reduce excessive secretion mucus and vasodilator substances;
- a second substance or combination of substances ensuring the reduction of air resistance at the level of of the nasal valve and the middle and lower horns by the formation of a "sliding mat" and the lubrication of the tissues of the nasal passages;
- the first substance or combination of substances is selected from the group consisting of: bromelain, Ruscus aculeatus extract and rutin
- the second substance or combination of substances is selected from the group consisting of: seawater, glycerin and phosphatidylcholine.
- the third substance or combination of substances is selected from the group of carrageenans.
- Bromelain enhances the sympathetic action of the smooth muscles of the nasal passages, so as to increase the basal tone, increase the nasal lumen and thus allow better penetration of air into the nasal passages. According to several studies and research, bromelain inhibits the production of prostaglandins responsible for inflammation, and acts on the immune system. Commission E has approved the use of bromelain to treat postoperative and post-traumatic edema, particularly nasal and paranasal sinuses. The anti-inflammatory action of bromelin on the nasal passages has also been confirmed.
- the extract of Ruscus aculeatus is intended to cause a vasoconstrictor action of the blood vessels in the form of an adrenergic type action on the smooth muscles of the vessel walls and to increase the nasal lumen and consequently to reduce the resistance to passage of air through the nasal passages.
- an extract of Ruscus aculeatus was more effective than placebo in relieving the symptoms of chronic venous insufficiency by causing vasoconstriction of the walls.
- veins [Lucker P, Jost V, Wolna P, et al. Efficacy and safety of ruscus extract compared to placebo in patients suffering from chronic venous insufficiency. Phytomedicine. 2000; 7 (suppl. 2): P-155].
- Rutin initiates a local anti-inflammatory action to reduce the excessive secretion of mucus and vasodilator substances, so as to reduce edema, vasodilation following inflammation and relaxation of tissue structures of smooth muscle and to allow as a result, an increase in nasal light.
- Rutin is part of the larger family of bioflavonoids. It is chemically very close to quercetin (another flavonoid), and it has antioxidant, anti-inflammatory, vasoprotective (protection of blood vessels) and anti-thrombotic properties (protection against blood clots). Rutin is present in several medicinal plants, including eucalyptus, hawthorn, ginkgo biloba and St. John's Wort.
- Glycerine and phosphatidylcholine provide lubrication functions.
- Seawater provides a sliding mat facilitating the passage of air through the nasal passages by reducing the mechanisms of resistance. Seawater has many therapeutic virtues and mainly locally internal, especially in nasal conditions. Local instillation of saline solution of sea water allows a decrease in inflammation of the nasal mucosa and obtaining a sliding mat. Seawater contains many mineral salts and trace elements that restore the hair functions of the mucosa.
- the nasal composition of the invention is remarkable in that it provides lubrication properties of the nasal mucosa and pharynx over a long period thanks to carrageenans, which have bioadhesive properties on the mucous membranes. All of these substances allow the nasal spray to reduce the resistance of the air in the nasal passages. This decrease consequently causes a decrease in the turbulence of the pharyngeal air flows caused by the increase in oral respiration.
- bromelain if it is present, represents of the order of 0.01 to 0.05% and preferably of the order of
- the ruscus extract if it is present, represents of the order of 0.03 to 0.07% and preferably of the order of 0.5% by weight of the composition
- rutin if it is present, represents on the order of 0.01 to 0.05% and preferably of the order of 0.15% by weight of the composition, at least one of the above substances being present in the composition.
- seawater if it is present, represents of the order of 0.5 to 5% and preferably of the order of 1% by weight of the composition
- glycerine if it is present, represents from 1 to 4% and preferably of the order of 2.65% by weight of the composition
- phosphatidylcholine if it is present, represents of the order of 0.5 to 2.5% and preferably of the order of 1.66% by weight of the composition, at least one of the above substances being present in the composition.
- the composition comprises a second substance / first substance weight ratio ranging from 20 to 100, especially from 30 to 80, or even from 40 to 70.
- the carrageenans represent of the order of 0.5 to 2% and preferably of the order of 1% of the composition.
- the composition may comprise a third substance / first substance weight ratio ranging from 1 to 50, in particular from 2 to 20 or even 5 to 15.
- the composition may comprise a second substance / third substance weight ratio ranging from 1 to 50, in particular from 2 to 20 or even 3 to 10.
- the subject of the invention is the use of the combination of first, second and third substance as an anti-snoring agent, in particular in large snorers, in a composition, in particular a nasal composition. .
- the invention also relates to the combination of the nasal composition above with an oral composition in the form of a mouth spray.
- the invention relates to a method for treating or preventing snoring of a subject wherein said subject receives a combination of a nasal composition above with an oral composition in the form of a spray. oral.
- the invention relates to the use of a nasal composition as defined above for the treatment or prevention of snoring in a subject, more particularly in a large snorer, said nasal composition being received by said subject in combination with an oral composition against snoring.
- the oral composition comprises at least one lubricating substance and at least one bioadhesive substance capable of adhering said lubricating substance to the mucocilliary cells situated at the level of the pharynx.
- the bioadhesive substance is selected from the group consisting of: polysaccharides, cellulose derivatives, acrylic derivatives or protein derivatives.
- the bioadhesive substance is a polysaccharide belonging to the carrageenan family.
- the oral composition comprises from about 0.5 to about 20% of bioadhesive substance, and in particular carrageenans.
- This composition contains from 1 to about 5%, and preferably from about 1.5 to 3%, of bioadhesive substance, and in particular of carrageenans. It may also contain about 5 to 20%, and about 10 to 15%, of bioadhesive substance, and in particular of carrageenans.
- the lubricant is a surfactant having a polar portion and a hydrophobic portion.
- the polar portion of the surfactant is selected from the group consisting of: glucose, sucrose, lactose, glycerol, xylose, peptides, amino acids, nucleotides.
- the hydrophobic portion is selected from the group consisting of: fatty acids, a fatty alcohol, a fatty amine, esters, glycerides, phospholipids.
- the hydrophobic part consists of phospholipids, for example phosphatidylcholine.
- This oral composition contains approximately 0.5 to 20% of lubricating substance, and in particular of phosphatidylcholine. It may contain preferably from 2 to 10% of lubricating substance, and in particular phosphatidylcholine.
- This oral composition further comprises one or more anti-inflammatory agent (s) and / or tonic (s) mucous membranes and pharyngeal tissue.
- the anti-inflammatory agent is an extract of Filipendula ulmaria, more particularly an extract of flowering heads of Filipendula ulmaria. It contains approximately 0.5 to 5% of anti-inflammatory agent, and in particular extract of flowering heads of Filipendula ulmaria.
- the tonic agent of mucous membranes and pharyngeal tissues is rose hips.
- the oral composition contains between 0.01 and 5% of tonic agent, and in particular of rose hips.
- the oral composition is in the form of an aerosol, more particularly a foam.
- a preferred oral composition contains:
- the composition of the oral spray lubricates the walls of the pharynx (uvula) and increase the tone of smooth muscle structures throughout the night thanks to the bioadhesive action of carrageenans.
- the nasal spray reduces nasal congestion, reduces chronic inflammation and lubricates the walls to facilitate the passage of airflow during inspiration and expiration.
- the invention thus also relates to a pack or a kit, or a set, comprising the two preceding compositions and a user manual so as to offer subjects suffering from snoring a treatment based on their combined action allowing s' to attack, simultaneously, the two causes of the noise caused by the big snorers.
- the two products that make up this kit or pack can be used in a specific order or on the contrary in an unordered manner.
- compositions composing this pack may be packaged in a container comprising several enclosures, or in separate containers. Containers may be packaged in a single package.
- compositions make it possible for the first time to treat the interactions between the nasal and pharyngeal physiological changes that cause snoring in large snorers. Indeed, there are several "vicious circles” that install progressively, reinforced by bouts of obstruction of the upper respiratory tract that induce changes in airflow. Only the combination of the technical solutions provided by the invention makes it possible to act simultaneously on the causes of snoring in order to significantly reduce, or even eliminate, the noise of snoring in loud snorers.
- the% are% by weight relative to the total weight of the composition.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002653920A CA2653920A1 (en) | 2006-06-01 | 2007-05-29 | Composition for controlling snoring, in the form of a nasal spray |
JP2009512650A JP2009538889A (en) | 2006-06-01 | 2007-05-29 | Anti-snoring composition as a nasal spray |
AU2007266903A AU2007266903A1 (en) | 2006-06-01 | 2007-05-29 | Composition for controlling snoring, in the form of a nasal spray |
EA200802263A EA200802263A1 (en) | 2006-06-01 | 2007-05-29 | COMPOSITION FOR THE FIGHT AGAINST SNAP IN THE FORM OF A NAZAL SPRAY |
EP07766110A EP2029162A1 (en) | 2006-06-01 | 2007-05-29 | Composition for controlling snoring, in the form of a nasal spray |
BRPI0711231-9A BRPI0711231A2 (en) | 2006-06-01 | 2007-05-29 | composition to combat snoring, use and pack |
TNP2008000493A TNSN08493A1 (en) | 2006-06-01 | 2008-11-28 | COMPOSITION FOR FIGHT AGAINST SNORING IN THE FORM OF A NASAL SPRAY |
NO20085138A NO20085138L (en) | 2006-06-01 | 2008-12-10 | Composition for controlling snoring in the form of nasal spray |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0651998 | 2006-06-01 | ||
FR0651998A FR2901705A1 (en) | 2006-06-01 | 2006-06-01 | COMPOSITION FOR FIGHT AGAINST SNORING IN THE FORM OF A NASAL SPRAY |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007138225A1 true WO2007138225A1 (en) | 2007-12-06 |
Family
ID=37103079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/051342 WO2007138225A1 (en) | 2006-06-01 | 2007-05-29 | Composition for controlling snoring, in the form of a nasal spray |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2029162A1 (en) |
JP (1) | JP2009538889A (en) |
AU (1) | AU2007266903A1 (en) |
BR (1) | BRPI0711231A2 (en) |
CA (1) | CA2653920A1 (en) |
EA (1) | EA200802263A1 (en) |
FR (1) | FR2901705A1 (en) |
MA (1) | MA30488B1 (en) |
NO (1) | NO20085138L (en) |
RU (1) | RU2008146887A (en) |
TN (1) | TNSN08493A1 (en) |
WO (1) | WO2007138225A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070178A2 (en) * | 2002-02-15 | 2003-08-28 | Cns, Inc. | Throat spray |
WO2004000272A1 (en) * | 2002-06-20 | 2003-12-31 | Novartis Consumer Health S.A. | Nasal compositions comprising a mucopolysaccharide and propylene glycol |
WO2004037237A1 (en) * | 2002-10-24 | 2004-05-06 | Immupharm A/S | Pharmaceutical compositions comprising flavonoids and menthol |
FR2876585A1 (en) * | 2004-10-20 | 2006-04-21 | Persee Medica | COMPOSITION FOR FIGHT AGAINST SNOW |
-
2006
- 2006-06-01 FR FR0651998A patent/FR2901705A1/en active Pending
-
2007
- 2007-05-29 BR BRPI0711231-9A patent/BRPI0711231A2/en not_active IP Right Cessation
- 2007-05-29 AU AU2007266903A patent/AU2007266903A1/en not_active Abandoned
- 2007-05-29 JP JP2009512650A patent/JP2009538889A/en not_active Withdrawn
- 2007-05-29 EA EA200802263A patent/EA200802263A1/en unknown
- 2007-05-29 WO PCT/FR2007/051342 patent/WO2007138225A1/en active Application Filing
- 2007-05-29 RU RU2008146887/15A patent/RU2008146887A/en unknown
- 2007-05-29 EP EP07766110A patent/EP2029162A1/en not_active Withdrawn
- 2007-05-29 CA CA002653920A patent/CA2653920A1/en not_active Abandoned
-
2008
- 2008-11-28 TN TNP2008000493A patent/TNSN08493A1/en unknown
- 2008-12-01 MA MA31432A patent/MA30488B1/en unknown
- 2008-12-10 NO NO20085138A patent/NO20085138L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070178A2 (en) * | 2002-02-15 | 2003-08-28 | Cns, Inc. | Throat spray |
WO2004000272A1 (en) * | 2002-06-20 | 2003-12-31 | Novartis Consumer Health S.A. | Nasal compositions comprising a mucopolysaccharide and propylene glycol |
WO2004037237A1 (en) * | 2002-10-24 | 2004-05-06 | Immupharm A/S | Pharmaceutical compositions comprising flavonoids and menthol |
FR2876585A1 (en) * | 2004-10-20 | 2006-04-21 | Persee Medica | COMPOSITION FOR FIGHT AGAINST SNOW |
Non-Patent Citations (1)
Title |
---|
NONE GIVEN: "Ruscus aculeatus (Butcher's broom).", ALTERNATIVE MEDICINE REVIEW, vol. 6, no. 6, 6 December 2001 (2001-12-06), pages 608 - 612, XP002404230 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009538889A (en) | 2009-11-12 |
FR2901705A1 (en) | 2007-12-07 |
AU2007266903A1 (en) | 2007-12-06 |
MA30488B1 (en) | 2009-06-01 |
RU2008146887A (en) | 2010-07-20 |
EA200802263A1 (en) | 2009-08-28 |
TNSN08493A1 (en) | 2010-04-14 |
NO20085138L (en) | 2009-02-27 |
BRPI0711231A2 (en) | 2011-08-30 |
EP2029162A1 (en) | 2009-03-04 |
CA2653920A1 (en) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6790465B2 (en) | Composition and method for treating snoring | |
US6845777B2 (en) | Composition to reduce or quit smoking addiction | |
JP5093967B2 (en) | Functional role of cannabinoids on autonomous stability during sleep | |
EP2026835B1 (en) | Nasal and buccal compositions comprising a ruscus aculeatus extract and rutin, for controlling snoring | |
WO2022097601A1 (en) | Composition for treating vascular disease, composition for preventing vascular disease, composition for treating hypertension, and composition for preventing hypertension | |
US20200138773A1 (en) | Compositions and methods for enhancing sexual pleasure and performance | |
CN1665507B (en) | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | |
EP2119446A1 (en) | Epithelium improving agent | |
EP2029162A1 (en) | Composition for controlling snoring, in the form of a nasal spray | |
EP1802347B1 (en) | Anti-snoring composition | |
CN104001162B (en) | A kind of medicament treating cardioneurosis and preparation method thereof | |
KR100638851B1 (en) | Drink for cleaning halitosis | |
AU2018436267A1 (en) | Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure | |
CN1289607A (en) | Capsule for treating epilepsy | |
CN105396071A (en) | Traditional Chinese medicine formula for treating children pneumonia | |
JP2009051757A (en) | Method for utilizing magnesium chloride for disease of creature such as cow, chicken and pig | |
CN106138740A (en) | A kind of Chinese medicine decoction for treating Qi deficiency blood stasis type cerebral infarction | |
Graedon et al. | National Geographic Complete Guide to Natural Home Remedies: 1,025 Easy Ways to Live Longer, Feel Better, and Enrich Your Life | |
Meenan et al. | Common Vocal Remedies: What Are They and Do They Really Work?, Part 2 | |
CN104547342A (en) | Rapid hemostasis external application powder for clinical nursing and preparation method of rapid hemostasis external application powder | |
Thomsen | SECTION A | |
BR102014005659A2 (en) | pharmaceutical composition for lubrication and flavoring of the oral cavity | |
CN107233369A (en) | A kind of alopecia areata wipes liquid | |
Sharma | Common diseases and cure | |
Meletis | Cough control the natural way |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07766110 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008111929 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2653920 Country of ref document: CA Ref document number: 2009512650 Country of ref document: JP Ref document number: MX/A/2008/015230 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200802263 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007266903 Country of ref document: AU Ref document number: 573339 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007766110 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10150/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007266903 Country of ref document: AU Date of ref document: 20070529 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2008146887 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0711231 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081128 |